The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
The focus is on wellness and personal care products
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
It is the first branded generic alternative to Fostair 100/6 pMDI
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
Subscribe To Our Newsletter & Stay Updated
